Phio Pharmaceuticals Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PHIO research report →
About the company
Phio Pharmaceuticals Corp. , a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies.
- CEO
- Robert L. Bitterman
- IPO
- 2012
- Employees
- 6
- HQ
- Marlborough, PA, US
Price Chart
- Market Cap
- $11.62M
- P/E
- -0.70
- P/S
- 0.00
- P/B
- 0.71
- EV/EBITDA
- 0.50
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -77.34%
- ROIC
- -67.14%
- Revenue
- $0 · 0.00%
- Net Income
- $-8,698,000 · -21.65%
- EPS
- $-1.45 · -59.34%
- Op Income
- $-9,220,000
- FCF YoY
- -12.34%
- 52W High
- $4.19
- 52W Low
- $0.81
- 50D MA
- $1.10
- 200D MA
- $1.34
- Beta
- 0.81
- Avg Volume
- 158.22K
Get TickerSpark's AI analysis on PHIO
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Bitterman Robert J | buy | 10,000 |
| Feb 5, 26 | Lockshin Curtis | other | 16,600 |
| Feb 5, 26 | Freeman Jonathan E | other | 16,600 |
| Feb 5, 26 | Deming David H | other | 23,800 |
| Feb 5, 26 | Carson Lisa Cabott | other | 47,000 |
| Feb 5, 26 | BRADFORD PATRICIA A | other | 18,500 |
| Feb 5, 26 | Bitterman Robert J | other | 120,000 |
| Dec 31, 25 | Bitterman Robert J | buy | 5,000 |
| Dec 23, 25 | Bitterman Robert J | buy | 5,000 |
| Nov 21, 25 | Bitterman Robert J | buy | 5,000 |
Our PHIO coverage
Recent articles, reports, and earnings notes.
No research on PHIO yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PHIO report →Similar companies
Peers in the same neighborhood.